Search

Your search keyword '"Jessop, Sophie"' showing total 23 results
Start Over Author "Jessop, Sophie"
23 results on '"Jessop, Sophie"'

2. Precision-guided treatment in high-risk pediatric cancers

Author

Lau, Loretta M. S., primary, Khuong-Quang, Dong-Anh, additional, Mayoh, Chelsea, additional, Wong, Marie, additional, Barahona, Paulette, additional, Ajuyah, Pamela, additional, Senapati, Akanksha, additional, Nagabushan, Sumanth, additional, Sherstyuk, Alexandra, additional, Altekoester, Ann-Kristin, additional, Fuentes-Bolanos, Noemi A., additional, Yeung, Veronica, additional, Sullivan, Ashleigh, additional, Omer, Natacha, additional, Diamond, Yonatan, additional, Jessop, Sophie, additional, Battaglia, Lauren, additional, Zhukova, Nataliya, additional, Cui, Louise, additional, Lin, Angela, additional, Gifford, Andrew J., additional, Fleuren, Emmy D. G., additional, Dalla-Pozza, Luciano, additional, Moore, Andrew S., additional, Khaw, Seong-Lin, additional, Eisenstat, David D., additional, Gottardo, Nicholas G., additional, Wood, Paul J., additional, Tapp, Heather, additional, Alvaro, Frank, additional, McCowage, Geoffrey, additional, Nicholls, Wayne, additional, Hansford, Jordan R., additional, Manoharan, Neevika, additional, Kotecha, Rishi S., additional, Mateos, Marion K., additional, Lock, Richard B., additional, Tyrrell, Vanessa, additional, Haber, Michelle, additional, Trahair, Toby N., additional, Cowley, Mark J., additional, Ekert, Paul G., additional, Marshall, Glenn M., additional, and Ziegler, David S., additional

Published
2024
Full Text
View/download PDF

3. Cardio-Oncology Recommendations for Pediatric Oncology Patients: An Australian and New Zealand Delphi Consensus

Author

Toro, Claudia, Felmingham, Ben, Jessop, Sophie, Celermajer, David S., Kotecha, Rishi S., Govender, Dinisha, Terese Hanna, Diane Marie, O'Connor, Matthew, Manudhane, Rebecca, Ayer, Julian, O'Sullivan, John, Sullivan, Michael, Costello, Ben, La Gerche, André, Walwyn, Thomas, Horvath, Lisa, Mateos, Marion K., Fulbright, Joy, Jadhav, Mangesh, Cheung, Michael, Eisenstat, David, Elliott, David A., and Conyers, Rachel

Published
2022
Full Text
View/download PDF

6. Precision-guided treatment improves outcomes for children with high-risk cancers

Author

Ziegler, David, primary, Lau, Loretta, additional, Khuong-Quang, Dong-Anh, additional, Mayoh, Chelsea, additional, Wong, Marie, additional, Barahona, Paulette, additional, Ajuyah, Pamela, additional, Senapati, Akanksha, additional, Nagabushan, Sumanth, additional, Sherstyuk, Alexandra, additional, Altekoester, Ann-Kristin, additional, Fuentes-Bolanos, Noemi, additional, Yeung, Veronica, additional, Sullivan, Ashleigh, additional, Diamond, Yonatan, additional, Omer, Natacha, additional, Jessop, Sophie, additional, Battaglia, Lauren, additional, Zhukova, Nataliya, additional, Cui, Louise, additional, Lin, Angela, additional, Gifford, Andrew, additional, Fleuren, Emmy, additional, Dalla-Pozza, Luciano, additional, Moore, Andrew, additional, Khaw, Seong_Lin, additional, Eisenstat, David, additional, Gottardo, Nick, additional, Wood, Paul, additional, Tapp, Heather, additional, Alvaro, Frank, additional, McCowage, Geoffrey, additional, Nicholls, Wayne, additional, Hansford, Jordan, additional, Manoharan, Neevika, additional, Kotecha, Rishi, additional, Mateos, Marion, additional, Lock, Richard, additional, Tyrrell, Vanessa, additional, Haber, Michelle, additional, Trahair, Toby, additional, Cowley, Mark, additional, Ekert, Paul, additional, and Marshall, Glenn, additional

Published
2023
Full Text
View/download PDF

7. Supplementary Tables S1-S7 from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

Author

Mayoh, Chelsea, primary, Mao, Jie, primary, Xie, Jinhan, primary, Tax, Gabor, primary, Chow, Shu-Oi, primary, Cadiz, Roxanne, primary, Pazaky, Karina, primary, Barahona, Paulette, primary, Ajuyah, Pamela, primary, Trebilcock, Peter, primary, Malquori, Angela, primary, Gunther, Kate, primary, Avila, Anica, primary, Yun, Doo Young, primary, Alfred, Stephanie, primary, Gopalakrishnan, Anjana, primary, Kamili, Alvin, primary, Wong, Marie, primary, Cowley, Mark J., primary, Jessop, Sophie, primary, Lau, Loretta M.S., primary, Trahair, Toby N., primary, Ziegler, David S., primary, Fletcher, Jamie I., primary, Gifford, Andrew J., primary, Tsoli, Maria, primary, Marshall, Glenn M., primary, Haber, Michelle, primary, Tyrrell, Vanessa, primary, Failes, Timothy W., primary, Arndt, Greg M., primary, Lock, Richard B., primary, Ekert, Paul G., primary, and Dolman, M. Emmy M., primary

Published
2023
Full Text
View/download PDF

8. Data from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

Author

Mayoh, Chelsea, primary, Mao, Jie, primary, Xie, Jinhan, primary, Tax, Gabor, primary, Chow, Shu-Oi, primary, Cadiz, Roxanne, primary, Pazaky, Karina, primary, Barahona, Paulette, primary, Ajuyah, Pamela, primary, Trebilcock, Peter, primary, Malquori, Angela, primary, Gunther, Kate, primary, Avila, Anica, primary, Yun, Doo Young, primary, Alfred, Stephanie, primary, Gopalakrishnan, Anjana, primary, Kamili, Alvin, primary, Wong, Marie, primary, Cowley, Mark J., primary, Jessop, Sophie, primary, Lau, Loretta M.S., primary, Trahair, Toby N., primary, Ziegler, David S., primary, Fletcher, Jamie I., primary, Gifford, Andrew J., primary, Tsoli, Maria, primary, Marshall, Glenn M., primary, Haber, Michelle, primary, Tyrrell, Vanessa, primary, Failes, Timothy W., primary, Arndt, Greg M., primary, Lock, Richard B., primary, Ekert, Paul G., primary, and Dolman, M. Emmy M., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figures and Figure Legends from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

Author

Mayoh, Chelsea, primary, Mao, Jie, primary, Xie, Jinhan, primary, Tax, Gabor, primary, Chow, Shu-Oi, primary, Cadiz, Roxanne, primary, Pazaky, Karina, primary, Barahona, Paulette, primary, Ajuyah, Pamela, primary, Trebilcock, Peter, primary, Malquori, Angela, primary, Gunther, Kate, primary, Avila, Anica, primary, Yun, Doo Young, primary, Alfred, Stephanie, primary, Gopalakrishnan, Anjana, primary, Kamili, Alvin, primary, Wong, Marie, primary, Cowley, Mark J., primary, Jessop, Sophie, primary, Lau, Loretta M.S., primary, Trahair, Toby N., primary, Ziegler, David S., primary, Fletcher, Jamie I., primary, Gifford, Andrew J., primary, Tsoli, Maria, primary, Marshall, Glenn M., primary, Haber, Michelle, primary, Tyrrell, Vanessa, primary, Failes, Timothy W., primary, Arndt, Greg M., primary, Lock, Richard B., primary, Ekert, Paul G., primary, and Dolman, M. Emmy M., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Materials and Methods from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

Author

Mayoh, Chelsea, primary, Mao, Jie, primary, Xie, Jinhan, primary, Tax, Gabor, primary, Chow, Shu-Oi, primary, Cadiz, Roxanne, primary, Pazaky, Karina, primary, Barahona, Paulette, primary, Ajuyah, Pamela, primary, Trebilcock, Peter, primary, Malquori, Angela, primary, Gunther, Kate, primary, Avila, Anica, primary, Yun, Doo Young, primary, Alfred, Stephanie, primary, Gopalakrishnan, Anjana, primary, Kamili, Alvin, primary, Wong, Marie, primary, Cowley, Mark J., primary, Jessop, Sophie, primary, Lau, Loretta M.S., primary, Trahair, Toby N., primary, Ziegler, David S., primary, Fletcher, Jamie I., primary, Gifford, Andrew J., primary, Tsoli, Maria, primary, Marshall, Glenn M., primary, Haber, Michelle, primary, Tyrrell, Vanessa, primary, Failes, Timothy W., primary, Arndt, Greg M., primary, Lock, Richard B., primary, Ekert, Paul G., primary, and Dolman, M. Emmy M., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figures from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

Author

Mayoh, Chelsea, primary, Mao, Jie, primary, Xie, Jinhan, primary, Tax, Gabor, primary, Chow, Shu-Oi, primary, Cadiz, Roxanne, primary, Pazaky, Karina, primary, Barahona, Paulette, primary, Ajuyah, Pamela, primary, Trebilcock, Peter, primary, Malquori, Angela, primary, Gunther, Kate, primary, Avila, Anica, primary, Yun, Doo Young, primary, Alfred, Stephanie, primary, Gopalakrishnan, Anjana, primary, Kamili, Alvin, primary, Wong, Marie, primary, Cowley, Mark J., primary, Jessop, Sophie, primary, Lau, Loretta M.S., primary, Trahair, Toby N., primary, Ziegler, David S., primary, Fletcher, Jamie I., primary, Gifford, Andrew J., primary, Tsoli, Maria, primary, Marshall, Glenn M., primary, Haber, Michelle, primary, Tyrrell, Vanessa, primary, Failes, Timothy W., primary, Arndt, Greg M., primary, Lock, Richard B., primary, Ekert, Paul G., primary, and Dolman, M. Emmy M., primary

Published
2023
Full Text
View/download PDF

12. High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

Author

Mayoh, Chelsea, primary, Mao, Jie, additional, Xie, Jinhan, additional, Tax, Gabor, additional, Chow, Shu-Oi, additional, Cadiz, Roxanne, additional, Pazaky, Karina, additional, Barahona, Paulette, additional, Ajuyah, Pamela, additional, Trebilcock, Peter, additional, Malquori, Angela, additional, Gunther, Kate, additional, Avila, Anica, additional, Yun, Doo Young, additional, Alfred, Stephanie, additional, Gopalakrishnan, Anjana, additional, Kamili, Alvin, additional, Wong, Marie, additional, Cowley, Mark J., additional, Jessop, Sophie, additional, Lau, Loretta M.S., additional, Trahair, Toby N., additional, Ziegler, David S., additional, Fletcher, Jamie I., additional, Gifford, Andrew J., additional, Tsoli, Maria, additional, Marshall, Glenn M., additional, Haber, Michelle, additional, Tyrrell, Vanessa, additional, Failes, Timothy W., additional, Arndt, Greg M., additional, Lock, Richard B., additional, Ekert, Paul G., additional, and Dolman, M. Emmy M., additional

Published
2023
Full Text
View/download PDF

14. Case Report: Rare IKZF1 Gene Fusions Identified in Neonate with Congenital KMT2A-Rearranged Acute Lymphoblastic Leukemia

Author

Eadie, Laura N., primary, Rehn, Jacqueline A., additional, Breen, James, additional, Osborn, Michael P., additional, Jessop, Sophie, additional, Downes, Charlotte E. J., additional, Heatley, Susan L., additional, McClure, Barbara J., additional, Yeung, David T., additional, Revesz, Tamas, additional, Saxon, Benjamin, additional, and White, Deborah L., additional

Published
2023
Full Text
View/download PDF

16. If we build it, will they come? Modeling of public hospital care requirements for the Australian Bragg Centre for Proton Therapy and Research.

Author

Jessop, Sophie, Penfold, Scott, Gorayski, Peter, Le, Hien, O'Connor, Matthew, Skelton, Kelly, and Tee, Hui Chin

Subjects
*PUBLIC hospitals, *HOSPITAL care, *PROTON therapy, *CHILDREN'S hospitals, *YOUNG adults
Abstract

Introduction: The Australian Bragg Centre for Proton Therapy and Research (ABCPTR) will be Australia's first proton beam therapy (PBT) facility. A model was developed to predict associated public hospital care requirements for patients during PBT, to facilitate resource planning for pediatric, adolescent and young adult (AYA), and adult public hospitals in South Australia. Methods: National incidence rates for specific cancer indications were obtained from the Australian Childhood Cancer Registry, Australian Institute of Health and Welfare and published data. Australian Bureau of Statistics national population projections were used to estimate new cases in 2025 and beyond. Radiation oncologists and pediatric oncologists from the Central Adelaide Local and Women's and Children's Health Network, along with international colleagues, provided guidance on chemotherapy utilization and inpatient admission estimates. Results: It was estimated 180 patients (40.4%) within the adult population (≥25 years) and 265 patients (59.6%) within the pediatric/AYA population (<25 years) would be eligible for PBT in 2025. There was no indication adult cancers would require concurrent outpatient/inpatient chemotherapy, in contrast with pediatric and AYA patients (59.5% and 62.8% outpatient and 18.9% and 41.9% inpatient, respectively). It was estimated 53% and 29% of pediatric and AYA patients could require inpatient admission for toxicity related to disease, concurrent chemotherapy or PBT. Conclusion: Associated public hospital care requirements related to the delivery of a national PBT service were estimated. This has particular implications for planning of the new Women's and Children's hospital, co‐located with the ABCPTR. True data accuracy will be determined on future data generation and analysis. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. Minimising Adverse Drug Reactions and Verifying Economic Legitimacy-Pharmacogenomics Implementation in Children (MARVEL- PIC): protocol for a national randomised controlled trial of pharmacogenomics implementation.

Author

Conyers R, Halman A, Moore C, Stenta T, Felmingham B, Collier L, Khatri D, Spelman T, Williams E, Dyas R, Kotecha RS, Jessop S, Mateos MK, Swen J, and Elliott DA

Subjects
Humans, Child, Prospective Studies, Randomized Controlled Trials as Topic, Neoplasms drug therapy, Neoplasms genetics, Multicenter Studies as Topic, Precision Medicine economics, Hematopoietic Stem Cell Transplantation, Drug-Related Side Effects and Adverse Reactions prevention & control, Pharmacogenetics
Abstract

Introduction: DNA-informed prescribing (termed pharmacogenomics, PGx) is the epitome of personalised medicine. Despite international guidelines existing, its implementation in paediatric oncology remains sparse., Methods and Analysis: Minimising Adverse Drug Reactions and Verifying Economic Legitimacy-Pharmacogenomics Implementation in Children is a national prospective, multicentre, randomised controlled trial assessing the impact of pre-emptive PGx testing for actionable PGx variants on adverse drug reaction (ADR) incidence in patients with a new cancer diagnosis or proceeding to haematopoetic stem cell transplant. All ADRs will be prospectively collected by surveys completed by parents/patients using the National Cancer Institute Pediatric Patient Reported [Ped-PRO]-Common Terminology Criteria for Adverse Events (CTCAE) (weeks 1, 6 and 12). Pharmacist will assess for causality and severity in semistructured interviews using the CTCAE and Liverpool Causality Assessment Tool. The primary outcome is a reduction in ADRs among patients with actionable PGx variants, where an ADR will be considered as any CTCAE grade 2 and above for non-haematological toxicities and any CTCAE grade 3 and above for haematological toxicities Cost-effectiveness of pre-emptive PGx (secondary outcome) will be compared with standard of care using hospital inpatient and outpatient data along with the validated Childhood Health Utility 9D Instrument. Power and statistics considerations: A sample size of 440 patients (220 per arm) will provide 80% power to detect a 24% relative risk reduction in the primary endpoint of ADRs (two-sided α=5%, 80% vs 61%), allowing for 10% drop-out., Ethics and Dissemination: The ethics approval of the trial has been obtained from the Royal Children's Hospital Ethics Committee (HREC/89083/RCHM-2022). The ethics committee of each participating centres nationally has undertaken an assessment of the protocol and governance submission., Trial Registration Number: NCT05667766., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results